查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1812374

放射性藥物市場

Radiopharmaceuticals Market
出版日期: | 出版商: Transparency Market Research | 英文 209 Pages | 商品交期: 2-10個工作天內

價格

放射性藥物市場-報告範圍

TMR 的全球放射性藥物市場報告研究了過去和當前的成長趨勢和機遇，以獲得 2025 年至 2035 年預測期內市場指標的寶貴見解。該報告提供了 2025 年至 2035 年期間全球放射性藥物市場的收入，以 2025 年為基準年，2035 年為預測年。報告中還提供了 2025 年至 2035 年期間全球放射性藥物市場的年複合成長率(CAGR %)。

本報告經過廣泛的研究後編寫。主要研究工作量較大，分析師訪問了關鍵意見領袖、產業領袖和輿論領袖。次要研究則參考了主要廠商的產品資料、年度報告、新聞稿和相關文件，以了解二輪車導航顯示器市場。

市場概況
2024年的市場價值 66億美元
2035年的市場價值 146億美元
複合年成長率 7.6%

本報告深入探討了全球二輪車導航顯示器市場的競爭格局。該報告確定了全球放射性藥物市場的主要參與者，並根據其各項屬性對每位參與者進行了分析。本報告對全球放射性藥物市場參與者的屬性進行了概述，包括公司概況、財務狀況、近期發展和 SWOT 分析。

全球放射性藥物市場報告解答的關鍵問題：

  • 預測期內，所有地區的血液分離術銷售額/收入為何？
  • 全球二輪車導航顯示器市場有哪些機會？
  • 市場的主要促進因素、限制因素、機會和威脅是什麼？
  • 在預測期內，哪個區域市場將以最快的複合年成長率擴張？
  • 預計哪個領域將在 2035 年創造全球最高收入？
  • 預測期內，哪個細分市場預計以最高複合年成長率擴張？
  • 在全球市場中經營的不同公司的市場地位如何？

放射性藥物市場-研究目標與研究方法

這份關於全球放射性藥物市場的綜合報告首先概述了研究範圍和目標。報告詳細闡述了本研究的目標、市場中的主要供應商和分銷商，以及產品核准的監管情況。

為了方便閱讀，本報告採用章節式編排，每個章節又細分為多個小節。報告包含詳盡的圖表，並適當穿插。各關鍵細分市場的實際值和預測值以圖形方式呈現，視覺上引人入勝。此外，報告也便於讀者比較過去和預測期末各關鍵細分市場的市佔率。

本報告從產品、最終用戶和地區角度分析了全球放射性藥物市場。該報告對每個標準下的關鍵細分市場進行了深入研究，並提供了2035年底每個細分市場的市場佔有率。這些寶貴的見解使市場利益相關者能夠在全球二輪車導航顯示器市場投資時做出明智的商業決策。

目錄

第1章：前言

第2章：假設與研究方法

第3章：執行摘要：全球市場

第4章：市場概況

  • 介紹
  • 概述
  • 市場動態
  • 2020年至2035年全球放射性藥物市場分析與預測

第5章：關鍵見解

  • FDA核准的放射性藥物產品
  • 重大疾病流行病學
  • 主要國家/地區報銷情況
  • 定價分析
  • 管道分析
  • 技術進步與發展
  • 放射治療領域先鋒標靶治療的見解
  • 各國/地區監管情況
  • 重要產業事件（產品發布、重要併購等）
  • 放射治療中心數量：主要國家

第6章：全球市場分析與預測：依放射性同位素

  • 介紹與定義
  • 主要發現/進展
  • 市值預測：依放射性同位素，2020 年至 2035 年
    • 診斷
      • 氟-18（F-18）
        • 氟脫氧葡萄糖（FDG）
        • 氟化鈉
        • 氟西可維因
        • 氟倍他吡爾
        • 氟倍他班
        • 其他
      • 鎵-68（Ga-68）
        • 多塔塔特
        • 多塔托克
        • PSMA-11
      • 锝-99m（Tc-99）
      • 碘-123（I-123）
      • 其他
    • 治療
      • 碘-131（I-131）
      • 釔-90（Y-90）
      • 镥-177（Lu-177）
        • Lu-PSMA-617
        • 露-DOTA-TATE
      • 其他
  • 市場吸引力分析：放射性同位素

第7章：全球市場分析與預測：按應用

  • 介紹與定義
  • 主要發現/進展
  • 市場價值預測：按應用，2020 年至 2035 年
    • 腫瘤學
      • 攝護腺癌
      • 乳癌
      • 神經內分泌腫瘤
      • 甲狀腺癌
      • 大腸直腸癌
      • 肝癌
      • 其他
    • 神經病學
      • 阿茲海默症
      • 帕金森氏症
      • 其他
    • 心臟病學
    • 其他
  • 市場吸引力分析：按應用

第8章：全球市場分析與預測：按最終用戶

  • 介紹與定義
  • 主要發現/進展
  • 市場價值預測：按最終用戶，2020 年至 2035 年
    • 醫院
    • 診斷和影像中心
    • 其他
  • 市場吸引力分析：按最終用戶

第9章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2020年至2035年
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第10章：北美市場分析與預測

第 11 章：歐洲市場分析與預測

第 12 章：亞太市場分析與預測

第13章：拉丁美洲市場分析與預測

第 14 章：中東和非洲市場分析與預測

第 15 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：按公司（2024年）
  • 公司簡介
    • Advanced Accelerator Applications
    • Bayer AG
    • Eli Lilly and Company
    • GE Healthcare
    • ITM Isotopen Technologien Munchen AG
    • Jubilant Pharma Limited
    • Lantheus Holdings, Inc.
    • Nihon Medi-Physics
    • Siemens Healthineers AG
    • Telix Pharmaceuticals
Product Code: TMRGL213

Radiopharmaceuticals Market- Scope of Report

TMR's report on the global Radiopharmaceuticals Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Radiopharmaceuticals Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Radiopharmaceuticals Marketfrom 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Radiopharmaceuticals Market .

Market Snapshot
Market Value in 2024US$ 6.6 Bn
Market Value in 2035US$ 14.6 Bn
CAGR7.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Radiopharmaceuticals Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Radiopharmaceuticals Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Radiopharmaceuticals Market .

The report delves into the competitive landscape of the global Radiopharmaceuticals Market . Key players operating in the global Radiopharmaceuticals Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Radiopharmaceuticals Marketprofiled in this report.

Key Questions Answered in Global Radiopharmaceuticals MarketReport:

  • What are the opportunities in the global Radiopharmaceuticals Market ?
  • What are the major drivers, restraints, opportunities, and threats in the Market ?
  • Which regional Market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the Market positions of different companies operating in the global Market ?

Radiopharmaceuticals Market- Research Objectives and Research Approach

The comprehensive report on the global Radiopharmaceuticals Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Radiopharmaceuticals Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Radiopharmaceuticals Market .

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Radiopharmaceuticals Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Radiopharmaceuticals Market Analysis and Forecast, 2020 to 2035
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. FDA Approved Radiopharmaceuticals Products
  • 5.2. Epidemiology of Major Diseases
  • 5.3. Reimbursement Scenario by key Countries/Regions
  • 5.4. Pricing Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Technological Advancements & Development
  • 5.7. Insights on Pioneering Targeted in Radiotherapy
  • 5.8. Regulatory Scenario by Country/Regions
  • 5.9. Key Industry Events (Product Launch, Key Mergers and Acquisitions, etc.)
  • 5.10. Number of Radiotherapy Centers: Major Country

6. Global Radiopharmaceuticals Market Analysis and Forecast, by Radioisotopes

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Radioisotopes, 2020 to 2035
    • 6.3.1. Diagnostics
      • 6.3.1.1. Fluorine-18 (F-18)
        • 6.3.1.1.1. Fludeoxyglucose (FDG)
        • 6.3.1.1.2. Sodium Fluoride
        • 6.3.1.1.3. Flucicovine
        • 6.3.1.1.4. Florbetapir
        • 6.3.1.1.5. Florbetaben
        • 6.3.1.1.6. Others
      • 6.3.1.2. Gallium-68 (Ga-68)
        • 6.3.1.2.1. Dotatate
        • 6.3.1.2.2. Dotatoc
        • 6.3.1.2.3. PSMA-11
      • 6.3.1.3. Technetium-99m (Tc-99)
      • 6.3.1.4. Iodine-123 (I-123)
      • 6.3.1.5. Others
    • 6.3.2. Therapy
      • 6.3.2.1. Iodine-131 (I-131)
      • 6.3.2.2. Yttrium-90 (Y-90)
      • 6.3.2.3. Lutetium-177 (Lu-177)
        • 6.3.2.3.1. Lu-PSMA-617
        • 6.3.2.3.2. Lu-DOTA-TATE
      • 6.3.2.4. Others
  • 6.4. Market Attractiveness Analysis, by Radioisotopes

7. Global Radiopharmaceuticals Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2020 to 2035
    • 7.3.1. Oncology
      • 7.3.1.1. Prostate Cancer
      • 7.3.1.2. Breast Cancer
      • 7.3.1.3. Neuroendocrine Tumors
      • 7.3.1.4. Thyroid Cancer
      • 7.3.1.5. Colorectal Cancer
      • 7.3.1.6. Liver Cancer
      • 7.3.1.7. Others
    • 7.3.2. Neurology
      • 7.3.2.1. Alzheimer's Disease
      • 7.3.2.2. Parkinson's Disease
      • 7.3.2.3. Others
    • 7.3.3. Cardiology
    • 7.3.4. Others
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Radiopharmaceuticals Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2020 to 2035
    • 8.3.1. Hospitals
    • 8.3.2. Diagnostics and Imaging Centers
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Radiopharmaceuticals Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020 to 2035
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Radiopharmaceuticals Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
    • 10.2.1. Diagnostics
      • 10.2.1.1. Fluorine-18 (F-18)
        • 10.2.1.1.1. Fludeoxyglucose (FDG)
        • 10.2.1.1.2. Sodium Fluoride
        • 10.2.1.1.3. Flucicovine
        • 10.2.1.1.4. Florbetapir
        • 10.2.1.1.5. Florbetaben
        • 10.2.1.1.6. Others
      • 10.2.1.2. Gallium-68 (Ga-68)
        • 10.2.1.2.1. Dotatate
        • 10.2.1.2.2. Dotatoc
        • 10.2.1.2.3. PSMA-11
      • 10.2.1.3. Technetium-99m (Tc-99)
      • 10.2.1.4. Iodine-123 (I-123)
      • 10.2.1.5. Others
    • 10.2.2. Therapy
      • 10.2.2.1. Iodine-131 (I-131)
      • 10.2.2.2. Yttrium-90 (Y-90)
      • 10.2.2.3. Lutetium-177 (Lu-177)
        • 10.2.2.3.1. Lu-PSMA-617
        • 10.2.2.3.2. Lu-DOTA-TATE
      • 10.2.2.4. Others
  • 10.3. Market Value Forecast, by Application, 2020 to 2035
    • 10.3.1. Oncology
      • 10.3.1.1. Prostate Cancer
      • 10.3.1.2. Breast Cancer
      • 10.3.1.3. Neuroendocrine Tumors
      • 10.3.1.4. Thyroid Cancer
      • 10.3.1.5. Colorectal Cancer
      • 10.3.1.6. Liver Cancer
      • 10.3.1.7. Others
    • 10.3.2. Neurology
      • 10.3.2.1. Alzheimer's Disease
      • 10.3.2.2. Parkinson's Disease
      • 10.3.2.3. Others
    • 10.3.3. Cardiology
    • 10.3.4. Others
  • 10.4. Market Value Forecast, by End-user, 2020 to 2035
    • 10.4.1. Hospitals
    • 10.4.2. Diagnostics and Imaging Centers
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2020 to 2035
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Radioisotopes
    • 10.6.2. By Application
    • 10.6.3. By End-user
    • 10.6.4. By Country

11. Europe Radiopharmaceuticals Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
    • 11.2.1. Diagnostics
      • 11.2.1.1. Fluorine-18 (F-18)
        • 11.2.1.1.1. Fludeoxyglucose (FDG)
        • 11.2.1.1.2. Sodium Fluoride
        • 11.2.1.1.3. Flucicovine
        • 11.2.1.1.4. Florbetapir
        • 11.2.1.1.5. Florbetaben
        • 11.2.1.1.6. Others
      • 11.2.1.2. Gallium-68 (Ga-68)
        • 11.2.1.2.1. Dotatate
        • 11.2.1.2.2. Dotatoc
        • 11.2.1.2.3. PSMA-11
      • 11.2.1.3. Technetium-99m (Tc-99)
      • 11.2.1.4. Iodine-123 (I-123)
      • 11.2.1.5. Others
    • 11.2.2. Therapy
      • 11.2.2.1. Iodine-131 (I-131)
      • 11.2.2.2. Yttrium-90 (Y-90)
      • 11.2.2.3. Lutetium-177 (Lu-177)
        • 11.2.2.3.1. Lu-PSMA-617
        • 11.2.2.3.2. Lu-DOTA-TATE
      • 11.2.2.4. Others
  • 11.3. Market Value Forecast, by Application, 2020 to 2035
    • 11.3.1. Oncology
      • 11.3.1.1. Prostate Cancer
      • 11.3.1.2. Breast Cancer
      • 11.3.1.3. Neuroendocrine Tumors
      • 11.3.1.4. Thyroid Cancer
      • 11.3.1.5. Colorectal Cancer
      • 11.3.1.6. Liver Cancer
      • 11.3.1.7. Others
    • 11.3.2. Neurology
      • 11.3.2.1. Alzheimer's Disease
      • 11.3.2.2. Parkinson's Disease
      • 11.3.2.3. Others
    • 11.3.3. Cardiology
    • 11.3.4. Others
  • 11.4. Market Value Forecast, by End-user, 2020 to 2035
    • 11.4.1. Hospitals
    • 11.4.2. Diagnostics and Imaging Centers
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 11.5.1. Germany
    • 11.5.2. UK
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Switzerland
    • 11.5.7. The Netherlands
    • 11.5.8. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Radioisotopes
    • 11.6.2. By Application
    • 11.6.3. By End-user
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Radiopharmaceuticals Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
    • 12.2.1. Diagnostics
      • 12.2.1.1. Fluorine-18 (F-18)
        • 12.2.1.1.1. Fludeoxyglucose (FDG)
        • 12.2.1.1.2. Sodium Fluoride
        • 12.2.1.1.3. Flucicovine
        • 12.2.1.1.4. Florbetapir
        • 12.2.1.1.5. Florbetaben
        • 12.2.1.1.6. Others
      • 12.2.1.2. Gallium-68 (Ga-68)
        • 12.2.1.2.1. Dotatate
        • 12.2.1.2.2. Dotatoc
        • 12.2.1.2.3. PSMA-11
      • 12.2.1.3. Technetium-99m (Tc-99)
      • 12.2.1.4. Iodine-123 (I-123)
      • 12.2.1.5. Others
    • 12.2.2. Therapy
      • 12.2.2.1. Iodine-131 (I-131)
      • 12.2.2.2. Yttrium-90 (Y-90)
      • 12.2.2.3. Lutetium-177 (Lu-177)
        • 12.2.2.3.1. Lu-PSMA-617
        • 12.2.2.3.2. Lu-DOTA-TATE
      • 12.2.2.4. Others
  • 12.3. Market Value Forecast, by Application, 2020 to 2035
    • 12.3.1. Oncology
      • 12.3.1.1. Prostate Cancer
      • 12.3.1.2. Breast Cancer
      • 12.3.1.3. Neuroendocrine Tumors
      • 12.3.1.4. Thyroid Cancer
      • 12.3.1.5. Colorectal Cancer
      • 12.3.1.6. Liver Cancer
      • 12.3.1.7. Others
    • 12.3.2. Neurology
      • 12.3.2.1. Alzheimer's Disease
      • 12.3.2.2. Parkinson's Disease
      • 12.3.2.3. Others
    • 12.3.3. Cardiology
    • 12.3.4. Others
  • 12.4. Market Value Forecast, by End-user, 2020 to 2035
    • 12.4.1. Hospitals
    • 12.4.2. Diagnostics and Imaging Centers
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. South Korea
    • 12.5.5. Australia & Newzealend
    • 12.5.6. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Radioisotopes
    • 12.6.2. By Application
    • 12.6.3. By End-user
    • 12.6.4. By Country/Sub-region

13. Latin America Radiopharmaceuticals Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
    • 13.2.1. Diagnostics
      • 13.2.1.1. Fluorine-18 (F-18)
        • 13.2.1.1.1. Fludeoxyglucose (FDG)
        • 13.2.1.1.2. Sodium Fluoride
        • 13.2.1.1.3. Flucicovine
        • 13.2.1.1.4. Florbetapir
        • 13.2.1.1.5. Florbetaben
        • 13.2.1.1.6. Others
      • 13.2.1.2. Gallium-68 (Ga-68)
        • 13.2.1.2.1. Dotatate
        • 13.2.1.2.2. Dotatoc
        • 13.2.1.2.3. PSMA-11
      • 13.2.1.3. Technetium-99m (Tc-99)
      • 13.2.1.4. Iodine-123 (I-123)
      • 13.2.1.5. Others
    • 13.2.2. Therapy
      • 13.2.2.1. Iodine-131 (I-131)
      • 13.2.2.2. Yttrium-90 (Y-90)
      • 13.2.2.3. Lutetium-177 (Lu-177)
        • 13.2.2.3.1. Lu-PSMA-617
        • 13.2.2.3.2. Lu-DOTA-TATE
      • 13.2.2.4. Others
  • 13.3. Market Value Forecast, by Application, 2020 to 2035
    • 13.3.1. Oncology
      • 13.3.1.1. Prostate Cancer
      • 13.3.1.2. Breast Cancer
      • 13.3.1.3. Neuroendocrine Tumors
      • 13.3.1.4. Thyroid Cancer
      • 13.3.1.5. Colorectal Cancer
      • 13.3.1.6. Liver Cancer
      • 13.3.1.7. Others
    • 13.3.2. Neurology
      • 13.3.2.1. Alzheimer's Disease
      • 13.3.2.2. Parkinson's Disease
      • 13.3.2.3. Others
    • 13.3.3. Cardiology
    • 13.3.4. Others
  • 13.4. Market Value Forecast, by End-user, 2020 to 2035
    • 13.4.1. Hospitals
    • 13.4.2. Diagnostics and Imaging Centers
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Argentina
    • 13.5.4. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Radioisotopes
    • 13.6.2. By Application
    • 13.6.3. By End-user
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Radiopharmaceuticals Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
    • 14.2.1. Diagnostics
      • 14.2.1.1. Fluorine-18 (F-18)
        • 14.2.1.1.1. Fludeoxyglucose (FDG)
        • 14.2.1.1.2. Sodium Fluoride
        • 14.2.1.1.3. Flucicovine
        • 14.2.1.1.4. Florbetapir
        • 14.2.1.1.5. Florbetaben
        • 14.2.1.1.6. Others
      • 14.2.1.2. Gallium-68 (Ga-68)
        • 14.2.1.2.1. Dotatate
        • 14.2.1.2.2. Dotatoc
        • 14.2.1.2.3. PSMA-11
      • 14.2.1.3. Technetium-99m (Tc-99)
      • 14.2.1.4. Iodine-123 (I-123)
      • 14.2.1.5. Others
    • 14.2.2. Therapy
      • 14.2.2.1. Iodine-131 (I-131)
      • 14.2.2.2. Yttrium-90 (Y-90)
      • 14.2.2.3. Lutetium-177 (Lu-177)
        • 14.2.2.3.1. Lu-PSMA-617
        • 14.2.2.3.2. Lu-DOTA-TATE
      • 14.2.2.4. Others
  • 14.3. Market Value Forecast, by Application, 2020 to 2035
    • 14.3.1. Oncology
      • 14.3.1.1. Prostate Cancer
      • 14.3.1.2. Breast Cancer
      • 14.3.1.3. Neuroendocrine Tumors
      • 14.3.1.4. Thyroid Cancer
      • 14.3.1.5. Colorectal Cancer
      • 14.3.1.6. Liver Cancer
      • 14.3.1.7. Others
    • 14.3.2. Neurology
      • 14.3.2.1. Alzheimer's Disease
      • 14.3.2.2. Parkinson's Disease
      • 14.3.2.3. Others
    • 14.3.3. Cardiology
    • 14.3.4. Others
  • 14.4. Market Value Forecast, by End-user, 2020 to 2035
    • 14.4.1. Hospitals
    • 14.4.2. Diagnostics and Imaging Centers
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Radioisotopes
    • 14.6.2. By Application
    • 14.6.3. By End-user
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2024)
  • 15.3. Company Profiles
    • 15.3.1. Advanced Accelerator Applications
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Bayer AG
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. Eli Lilly and Company
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. GE Healthcare
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. ITM Isotopen Technologien Munchen AG
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. Jubilant Pharma Limited
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. Lantheus Holdings, Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. Nihon Medi-Physics
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. Siemens Healthineers AG
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments
    • 15.3.10. Telix Pharmaceuticals
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. Business Strategies
      • 15.3.10.5. Recent Developments

List of Tables

  • Table 01: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
  • Table 02: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
  • Table 03: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
  • Table 04: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
  • Table 05: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
  • Table 06: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
  • Table 07: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
  • Table 08: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
  • Table 09: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
  • Table 10: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
  • Table 11: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
  • Table 12: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country, 2020 to 2035
  • Table 13: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
  • Table 14: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
  • Table 15: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
  • Table 16: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
  • Table 17: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
  • Table 18: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
  • Table 19: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
  • Table 20: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
  • Table 21: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
  • Table 22: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
  • Table 23: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
  • Table 24: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
  • Table 25: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
  • Table 26: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
  • Table 27: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
  • Table 28: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
  • Table 29: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
  • Table 30: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
  • Table 31: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
  • Table 32: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
  • Table 33: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
  • Table 34: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
  • Table 35: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
  • Table 36: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
  • Table 37: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
  • Table 38: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
  • Table 39: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
  • Table 40: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
  • Table 41: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
  • Table 42: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
  • Table 43: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
  • Table 44: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
  • Table 45: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
  • Table 46: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
  • Table 47: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
  • Table 48: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
  • Table 49: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
  • Table 50: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
  • Table 51: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
  • Table 52: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
  • Table 53: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
  • Table 54: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
  • Table 55: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
  • Table 56: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
  • Table 57: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
  • Table 58: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
  • Table 59: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
  • Table 60: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
  • Table 61: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
  • Table 62: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
  • Table 63: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
  • Table 64: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
  • Table 65: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
  • Table 66: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035

List of Figures

  • Figure 01: Global Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
  • Figure 02: Global Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
  • Figure 03: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Diagnostics, 2020 to 2035
  • Figure 04: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Therapy, 2020 to 2035
  • Figure 05: Global Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 06: Global Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 07: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Oncology, 2020 to 2035
  • Figure 08: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Neurology, 2020 to 2035
  • Figure 09: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Cardiology, 2020 to 2035
  • Figure 10: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Others, 2020 to 2035
  • Figure 11: Global Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 12: Global Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 13: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Hospitals, 2020 to 2035
  • Figure 14: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Diagnostics and Imaging Centers, 2020 to 2035
  • Figure 15: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Others, 2020 to 2035
  • Figure 16: Global Radiopharmaceuticals Market Value Share Analysis, By Region, 2024 and 2035
  • Figure 17: Global Radiopharmaceuticals Market Attractiveness Analysis, By Region, 2025 to 2035
  • Figure 18: North America - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
  • Figure 19: North America - Radiopharmaceuticals Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 20: North America - Radiopharmaceuticals Market Attractiveness Analysis, by Country, 2025 to 2035
  • Figure 21: North America - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
  • Figure 22: North America - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
  • Figure 23: North America - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 24: North America - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 25: North America - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 26: North America - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 27: Europe - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
  • Figure 28: Europe - Radiopharmaceuticals Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 29: Europe - Radiopharmaceuticals Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
  • Figure 30: Europe Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
  • Figure 31: Europe Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
  • Figure 32: Europe - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 33: Europe - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 34: Europe - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 35: Europe - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 36: Asia Pacific - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
  • Figure 37: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 38: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
  • Figure 39: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
  • Figure 40: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
  • Figure 41: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 42: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 43: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 44: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 45: Latin America - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
  • Figure 46: Latin America - Radiopharmaceuticals Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 47: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
  • Figure 48: Latin America - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
  • Figure 49: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
  • Figure 50: Latin America - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 51: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 52: Latin America - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 53: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 54: Middle East & Africa - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
  • Figure 55: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 56: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
  • Figure 57: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
  • Figure 58: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
  • Figure 59: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 60: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 61: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 62: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035